Harnessing host immune responses to preneoplasia: promise and challenges.
Preneoplastic lesions are more common than clinical cancer and define a population at increased risk for the development of malignancy. Recent studies suggest that the immune system has the capacity to recognize these lesions, and enrichment of preneoplasia-specific immune effectors can be detected in the tumor bed of some preneoplastic lesions such as monoclonal gammopathies. Here, I discuss the promise and challenges of harnessing the immune response against preneoplasia. Approaches to boost the natural host response to these lesions may have a major impact on reducing net cancer burden.
Dhodapkar
Madhav V
MV
Laboratory of Tumor Immunology and Immunotherapy, Rockefeller University, New York, NY 10021, USA. dhodapm@rockefeller.edu
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D006801:Humans; D007107:Immune System / Q000276:immunology; D007157:Immunologic Surveillance; D023421:Models, Animal; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control*; D011230:Precancerous Conditions / Q000276:immunology*
D000951:Antigens, Neoplasm